Quarterly ResultAug 12, 2026, 05:02 PM
SeaStar Medical Q2 Net Loss $3.73M; Going Concern Warning Issued
AI Summary
SeaStar Medical Holding Corp. reported a net loss of $3.73 million for the second quarter of 2026, an increase from $2.00 million in the prior year. The company issued a going concern warning, stating that its current cash of $6.96 million is insufficient to fund operations for the next 12 months. Despite a significant 82% increase in net revenue to $0.62 million for the quarter, operating expenses, particularly R&D, also rose sharply. The company continues to advance its medical device technology, including its FDA-approved QUELIMMUNE product and a pivotal clinical trial for adult SCD.
Key Highlights
- Reported Q2 2026 net loss of $3.73 million, up from $2.00 million in Q2 2025.
- Issued a going concern warning, citing insufficient cash for 12 months of operations.
- Generated Q2 2026 net revenue of $0.62 million, an 82% increase from Q2 2025.
- Cash on hand decreased to $6.96 million as of June 30, 2026, from $11.98 million at year-end 2025.
- Net cash used in operating activities was $5.76 million for the first six months of 2026.
- Raised $1.2 million net from equity offerings (SEPA and ATM) in H1 2026.
- FDA approved QUELIMMUNE (pediatric SCD) on February 21, 2024, under HDE.
Price Impact
More from ICU